▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1089 by analyst upside · 2026-06-27
RARE
Ultragenyx Pharmaceutical Inc.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+69.2%
implied upside to consensus target
Current Price $30.77
Consensus Target $52.05
Bull Target $96.0
Bear Target $25.0
Analysts Covering 19
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
12
Hold
2
Sell
0
52-Week Low $18.29
52-Week High $42.37
YTD Return +30.4%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E 31.9x
EPS (TTM) $-6.10
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $670M
Profit Margin -90.9%
52-WEEK RANGE
52-Week Low $18.29
52-Week High $42.37
Current Price $30.77
Bear Target $25.0
Bull Target $96.0
● Now $30.77 ● Target $52.05
TRADING DATA
Avg Volume 1.8M
YTD Return +30.4%
Analyst Count 19
Consensus Buy
Upside to Target +69.2%
Last Updated 2026-06-27

ANALYST SUMMARY

Ultragenyx Pharmaceutical Inc. (RARE) is currently trading at $30.77 with a Wall Street consensus price target of $52.05, implying potential upside of 69.2% over the next 12 months. 19 analysts currently cover RARE, with a consensus rating of Buy - 89% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $96.0, while the most cautious has a target of $25.0.

RARE operates in the Healthcare sector with a market capitalisation of $3B. The stock is up 30.4% year-to-date and is currently trading near the upper end of its 52-week range of $18.29 – $42.37.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

TMDX +71.4%
TransMedics Group, Inc.
$2B · P/E 15.7x · Buy
WAY +70.0%
Waystar Holding Corp.
$4B · P/E 29.7x · Buy
OPCH +31.0%
Option Care Health, Inc.
$3B · P/E 16.8x · Buy
PBH +35.2%
Prestige Consumer Healthcare Inc.
$2B · P/E 12.6x · Buy
ADMA +101.1%
ADMA Biologics, Inc.
$2B · P/E 12.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for RARE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Cantor Fitzgerald reit
Overweight → Overweight 2024-10-22 40% win rate (10 calls)
TD Cowen — Reiterated
Buy → Buy 2024-10-21 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2024-10-01 40% win rate (10 calls)
RBC Capital reit
Outperform → Outperform 2024-09-26 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2024-09-20 40% win rate (10 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-09-16 40% win rate (10 calls)
Barclays — Reiterated
Overweight → Overweight 2024-08-05 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2024-08-02 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
23/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →